HB 1734
Alternative Names: HB-1734Latest Information Update: 27 Nov 2023
At a glance
- Originator Huabo Biopharm
- Class Antifibrotics; Bispecific antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 17 modulators; Interleukin 36 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Idiopathic pulmonary fibrosis; Systemic scleroderma
Most Recent Events
- 27 Nov 2023 Preclinical trials in Idiopathic pulmonary fibrosis in China (Parenteral), before November 2023 (Huabo Biopharm pipeline, November 2023)
- 27 Nov 2023 Preclinical trials in Systemic scleroderma in China (Parenteral), before November 2023 (Huabo Biopharm pipeline, November 2023)